Crescent Biopharma, Inc. (CBIO)
Automate Your Wheel Strategy on CBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including CBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CBIO
- Rev/Share 0.3364
- Book/Share 1.2839
- PB 7.1891
- Debt/Equity 0.0263
- CurrentRatio 6.6274
- ROIC -0.7212
- MktCap 254348959.0
- FreeCF/Share -0.5418
- PFCF -5.1676
- PE -14.9838
- Debt/Assets 0.0222
- DivYield 0
- ROE -0.8461
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CBIO | Piper Sandler | -- | Overweight | -- | $35 | Jan. 28, 2026 |
| Initiation | CBIO | Guggenheim | -- | Buy | -- | $35 | Jan. 21, 2026 |
| Initiation | CBIO | Jefferies | -- | Buy | -- | $26 | Aug. 25, 2025 |
| Initiation | CBIO | H.C. Wainwright | -- | Buy | -- | $25 | Aug. 11, 2025 |
| Initiation | CBIO | Wedbush | -- | Outperform | -- | $27 | July 14, 2025 |
| Initiation | CBIO | Stifel | -- | Buy | -- | $28 | June 25, 2025 |
News
Crescent Biopharma Announces Grants of Inducement Awards
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 451,448 shares of the Company's ordinary shares to eight non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on November 14, 2025 and were material to each employee's acceptance …
Read More
About Crescent Biopharma, Inc. (CBIO)
- IPO Date 2014-01-10
- Website https://crescentbiopharma.com
- Industry Biotechnology
- CEO Joshua T. Brumm
- Employees 41